tbuckley/cabot-search huggingface dataset:
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
Authors: Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot, Carlo Gambacorti-Passerini
Journal: Journal of Hematology & Oncology (2018)

Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy of bosutinib as first-line treatment in adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). The most common adverse events (AEs) of any grade in bosutinib-treated patients in BFORE were diarrhea, nausea, thrombocytopenia, increased alanine aminotransferase, and increased aspartate aminotransferase, consistent with the most commonly reported AEs in earlier studies. To balance the efficacy and tolerability of treatment to optimize patient adherence with medications, treating physicians commonly use various strategies such as initiating treatment at a lower dose, dose reduction, or dose interruption, depending on the type and severity of the AEs and the clinical setting. In light of the recent data from first-line treatment, an expert panel of hematologists reviewed management strategies for the use of bosutinib in treatment of CP-CML and made the recommendations reported here. Although the panel focused on first-line treatment, the principles can be for the most part extended to bosutinib use in later lines of treatment. Recommendations include advice regarding prophylaxis and management for diarrhea. The panel also considered optimum timing for referral to a specialist for specific AEs. Across the commonly occurring AEs, the panel highlighted the importance of education and communication with patients about anticipated AEs.
MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study
Authors: Marc S Raab, Manik Chatterjee, Hartmut Goldschmidt, Hermine Agis, Igor Blau, Hermann Einsele, Monika Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Rollig, Katja Weisel, Tiantom Jarutat, Dominika Weinelt, Mark Winderlich, Christian Peschel
Journal: Blood (2018)
Providing Comprehensive Health Care for Undocumented People in the United States
Authors: Marlene Martin
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 16395: Comparing Cardiopulmonary Exercise Measures of Men and Women With HFrEF and Their Relationship to Prognosis: The Henry Ford HospITal CardioPulmonary Exercise Testing (FIT-CPET) Project
Authors: Jonathan K Ehrman, Clinton A Brawner, Heather Aldred, Ali Shfiq, Raakesh Hassan, David Lanfear, Steven J Keteyian
Journal: Circulation (2015)

Introduction: Several cardiopulmonary exercise test (CPET) variables (e.g., peak oxygen consumption (VO2), ventilatory efficiency (VE-VCO2) slope, and % predicted peak VO2 (%pVO2)) are regularly used to estimate prognosis in patients with systolic heart failure (HFrEF). Although known sex differences in physiology (i.e., muscle mass, lung volume) result in lower peak VO2 values in healthy women vs. men, this influence on CPET variables and subsequent prognosis in patients with HFrEF is not well described. Purpose: Compare the peak VO2, VE-VCO2 slope and %pVO2 values in men and women that correspond to prognosis using the International Society of Heart Transplant (ISHT) reported North American 1 and 3-y cardiac transplant survival rates (i.e., 86% and 79%, respectively). Methods: Patients with a CPET between 1997 and 2010 were identified. HFrEF was confirmed through a manual query of the medical record. Deaths through December 2011 were identified from the National Death Index. Receiver operator characteristic (ROC) curves were developed for each CPET measure and the threshold values and area under the curve (AUC) values associated with 86% and 79% specificity for each sex were determined. Results: A total of 1,201 patients (33% female; 55% Black; 33% ischemic; age = 55 + 13 y; BMI = 31 +7 kg.m-2; EF = 22 + 9%) were included in this analysis. Specificity threshold values and the corresponding AUC, for each CPX variable, are shown in the Table. At 1-y there were 167 (14%) deaths with a 10% event rate for women and 16% for men. At 3-y there were 335 (31%) deaths with a 25% event rate for women and 35% for men. Conclusions: In this large, racially diverse population both peak VO2 and %pVO2 had clinically meaningful differences for risk stratification thresholds depending on sex. This was not true for VE-VCO2 slope. Clinical decisions regarding the need for advanced therapies such as transplant or ventricular assist devices, when based on peak VO2 or %pVO2, might consider the patient’s sex.
Abstract 17467: Characteristics and Long-Term Outcomes in Patients With Marfan Syndrome: A Tertiary Care Center Experience
Authors: Kevin Chen, Erika Hutt, Vidyasagar Kalahasti, Eric Roselli, Carlos Godoy, Alaa Alashi, Donald Hammer, Brian Griffin, Milind Desai, Lars Svensson
Journal: Circulation (2017)

Background: We sought to assess characteristics and longer-term outcomes of patients with Marfan syndrome (MFS) evaluated at a high-volume tertiary care center. Methods: We included 749 MFS patient...
Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock
Authors: Alan E. Jones, Michael A. Puskarich, Nathan I. Shapiro, Faheem W. Guirgis, Michael Runyon, Jason Y. Adams, Robert Sherwin, Ryan Arnold, Brian W. Roberts, Michael C. Kurz, Henry E. Wang, Jeffrey A. Kline, D. Mark Courtney, Stephen Trzeciak, Sarah A. Sterling, Utsav Nandi, Deepti Patki, Kert Viele
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Sepsis induces profound metabolic derangements, while exogenous levocarnitine mitigates metabolic dysfunction by enhancing glucose and lactate oxidation and increasing fatty acid shuttling. Previous trials in sepsis suggest beneficial effects of levocarnitine on patient-centered outcomes. <h3>Objectives</h3> To test the hypothesis that levocarnitine reduces cumulative organ failure in patients with septic shock at 48 hours and, if present, to estimate the probability that the most efficacious dose will decrease 28-day mortality in a pivotal phase 3 clinical trial. <h3>Design, Setting, and Participants</h3> Multicenter adaptive, randomized, blinded, dose-finding, phase 2 clinical trial (Rapid Administration of Carnitine in Sepsis [RACE]). The setting was 16 urban US medical centers. Participants were patients aged 18 years or older admitted from March 5, 2013, to February 5, 2018, with septic shock and moderate organ dysfunction. <h3>Interventions</h3> Within 24 hours of identification, patients were assigned to 1 of the following 4 treatments: low (6 g), medium (12 g), or high (18 g) doses of levocarnitine or an equivalent volume of saline placebo administered as a 12-hour infusion. <h3>Main Outcomes and Measures</h3> The primary outcome required, first, a greater than 90% posterior probability that the most promising levocarnitine dose decreases the Sequential Organ Failure Assessment (SOFA) score at 48 hours and, second (given having met the first condition), at least a 30% predictive probability of success in reducing 28-day mortality in a subsequent traditional superiority trial to test efficacy. <h3>Results</h3> Of the 250 enrolled participants (mean [SD] age, 61.7 [14.8] years; 56.8% male), 35, 34, and 106 patients were adaptively randomized to the low, medium, and high levocarnitine doses, respectively, while 75 patients were randomized to placebo. In the intent-to-treat analysis, the fitted mean (SD) changes in the SOFA score for the low, medium, and high levocarnitine groups were −1.27 (0.49), −1.66 (0.38), and −1.97 (0.32), respectively, vs −1.63 (0.35) in the placebo group. The posterior probability that the 18-g dose is superior to placebo was 0.78, which did not meet the a priori threshold of 0.90. Mortality at 28 days was 45.9% (34 of 74) in the placebo group compared with 43.3% (45 of 104) for the most promising levocarnitine dose (18 g). Similar findings were noted in the per-protocol analysis. <h3>Conclusions and Relevance</h3> In this dose-finding, phase 2 adaptive randomized trial, the most efficacious dose of levocarnitine (18 g) did not meaningfully reduce cumulative organ failure at 48 hours. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01665092
Myelodysplastic Syndrome and Acute Myeloid Leukemia Risk Associated With Solid Tumor Chemotherapy
Authors: Shyam A. Patel
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 18939: Risk of Cardiovascular Events Amongst Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Authors: Eric Carelli, Edward Hulten, Alice Dragomir, Jacinthe Boulet, Lyne Nadeau, Jay Brophy, Negar Mousavi
Journal: Circulation (2017)

Introduction: Prostate Cancer (PC) is the most common cancer and the third leading cause of cancer death amongst Canadian men. Androgen deprivation therapy (ADT) is the first-line treatment for PC....
Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection
Authors: José Carlos Valle-Casuso, Mathieu Angin, Stevenn Volant, Caroline Passaes, Valérie Monceaux, Anastassia Mikhailova, Katia Bourdic, Véronique Avettand-Fenoel, Faroudy Boufassa, Marc Sitbon, Olivier Lambotte, Maria-Isabel Thoulouze, Michaela Müller-Trutwin, Nicolas Chomont, Asier Sáez-Cirión
Journal: Cell Metabolism (2018)
Tuberculosis and impaired IL-23–dependent IFN-γ immunity in humans homozygous for a common <i>TYK2</i> missense variant
Authors: Stéphanie Boisson-Dupuis, Noe Ramirez-Alejo, Zhi Li, Etienne Patin, Geetha Rao, Gaspard Kerner, Che Kang Lim, Dimitry N. Krementsov, Nicholas Hernandez, Cindy S. Ma, Qian Zhang, Janet Markle, Ruben Martinez-Barricarte, Kathryn Payne, Robert Fisch, Caroline Deswarte, Joshua Halpern, Matthieu Bouaziz, Jeanette Mulwa, Durga Sivanesan, Tomi Lazarov, Rodrigo Naves, Patricia Garcia, Yuval Itan, Bertrand Boisson, Alix Checchi, Fabienne Jabot-Hanin, Aurélie Cobat, Andrea Guennoun, Carolyn C. Jackson, Sevgi Pekcan, Zafer Caliskaner, Jaime Inostroza, Beatriz Tavares Costa-Carvalho, Jose Antonio Tavares de Albuquerque, Humberto Garcia-Ortiz, Lorena Orozco, Tayfun Ozcelik, Ahmed Abid, Ismail Abderahmani Rhorfi, Hicham Souhi, Hicham Naji Amrani, Adil Zegmout, Frédéric Geissmann, Stephen W. Michnick, Ingrid Muller-Fleckenstein, Bernhard Fleckenstein, Anne Puel, Michael J. Ciancanelli, Nico Marr, Hassan Abolhassani, María Elvira Balcells, Antonio Condino-Neto, Alexis Strickler, Katia Abarca, Cory Teuscher, Hans D. Ochs, Ismail Reisli, Esra H. Sayar, Jamila El-Baghdadi, Jacinta Bustamante, Lennart Hammarström, Stuart G. Tangye, Sandra Pellegrini, Lluis Quintana-Murci, Laurent Abel, Jean-Laurent Casanova
Journal: Science Immunology (2018)

Homozygosity for the P1104A missense variant of the TYK2 Janus kinase is common monogenic etiology of primary tuberculosis.
Abstract 14925: Vagal Antagonism is Accentuated During Beta-adrenergic Stimulation in Long-term Aerobic Exercised Calsequestrin2 Knockout Mice, Which Restricts Heart Rate Acceleration and Paradoxically Increases Abnormal Ryanodine Receptor Calcium Leak in Ventricular Myocytes
Authors: Hsiang-Ting Ho, Senthil Thambidorai, Bjorn C Knollmann, George E Billman, Sandor Gyorke, Anuradha Kalyanasundaram
Journal: Circulation (2017)

Introduction: Despite well-known cardiac benefits of regular physical activity, prescribing exercise therapy for patients with arrhythmias including Catecholaminergic Polymorphic Ventricular Tachyc...
A Surface-Induced Asymmetric Program Promotes Tissue Colonization by Pseudomonas aeruginosa
Authors: Benoît-Joseph Laventie, Matteo Sangermani, Fabienne Estermann, Pablo Manfredi, Rémi Planes, Isabelle Hug, Tina Jaeger, Etienne Meunier, Petr Broz, Urs Jenal
Journal: Cell Host & Microbe (2018)
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Authors: Nasreen Khalil, Helene Manganas, Christopher J. Ryerson, Shane Shapera, Andre M. Cantin, Paul Hernandez, Eric E. Turcotte, Joseph M. Parker, John E. Moran, Gary R. Albert, Renata Sawtell, Aline Hagerimana, Pierre Laurin, Lyne Gagnon, Frank Cesari, Martin Kolb
Journal: European Respiratory Journal (2018)

PBI-4050 is a novel orally active small-molecule compound with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis. We present results from our first clinical study of PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF). This 12-week open-label study explored the safety, efficacy and pharmacokinetics of daily oral doses of 800 mg PBI-4050 alone and in combination with nintedanib or pirfenidone in patients with predominantly mild or moderate IPF. Nine patients received PBI-4050 alone, 16 patients received PBI-4050 with nintedanib and 16 patients received PBI-4050 with pirfenidone. PBI-4050 alone or in combination with nintedanib or pirfenidone was well tolerated. Pharmacokinetic profiles for PBI-4050 were similar in the PBI-4050 alone and PBI-4050+nintedanib groups but reduced in the PBI-4050+pirfenidone group, suggesting a drug–drug interaction. There were no significant changes in forced vital capacity (FVC), either in % predicted or mL, from baseline to week 12 for PBI-4050 alone or PBI-4050+nintedanib. In contrast, a statistically significant reduction (p&lt;0.024) in FVC % pred was seen for PBI-4050+pirfenidone after 12 weeks. There were no safety concerns with PBI-4050 alone or in combination with nintedanib or pirfenidone in IPF patients. The stability of FVC between baseline and week 12 looked encouraging for PBI-4050 alone and in combination with nintedanib.
R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial
Authors: Andres JM Ferreri, Teresa Calimeri, Gian Marco Conte, Dario Cattaneo, Federico Fallanca, Maurilio Ponzoni, Eloise Scarano, Marianna Sassone, Salvatore Perrone, Caterina Cecchetti, Paolo Lopedote, Fiorella Ilariucci, Roberta Rudà, Emanuele Angelucci, Carlo Visco, Francesco Pisani, Alberto Fabbri, Luigi Petrucci, Marco Bregni, Dario Marino, Guido Gini, Fabio Ciceri, Angelo Corti, Nicoletta Anzalone
Journal: Blood (2018)
Abstract 14479: Abrupt Withdrawal of Losartan Therapy Increases Circulating Transforming Growth Factor Beta and Accelerates Aortic Root Growth in a Mouse Model of Marfan Syndrome
Authors: Florian S Schoenhoff, Jennifer P Habashi, David Huso, Hamza Aziz, Jefferson Doyle, Peter Matt, Guosheng Liu, Jennifer E Van Eyk, Harry C Dietz
Journal: Circulation (2010)

Objective: The AT1 receptor blocker losartan has shown the ability to attenuate TGFβ signaling and aneurysm progression in a mouse model of Marfan syndrome (MFS). Losartan is known to be teratogeni...
Abstract 14228: Endogenous Sex Hormone Levels and Risk for Incident Cardiovascular Disease and Heart Failure in Post-Menopausal Women: The Multi Ethnic Study of Atherosclerosis (MESA)
Authors: Di Zhao, Eliseo Guallar, Pamela H Ouyang, Vinita Subramanya, Dhananjay Vaidya, Chiadi Ndumele, Sanjiv J Shah, Alain G Bertoni, Joao A Lima, Matthew J Budoff, Matthew A Allison, Wendy S Post, Erin D Michos
Journal: Circulation (2017)

Background: Higher androgen and lower estrogen levels are associated with cardiovascular disease (CVD) risk factors in women. However, studies on sex hormones and incident CVD events in women have ...
Evaluation of effects of over-expression of osteoprotegerin in C4-2 prostate cancer cells on character of bone metastasis
Authors: Lisha G. Brown, Jeffrey A. Kiefer, Janna E. Quinn, Austin M. Odman, Julie M. Blair, Robert L. Vessella, Eva Corey
Journal: Cancer Research (2004)

1845   Advanced prostate cancer (CaP) metastasizes frequently to the skeleton. CaP cells present in bone alter the normal physiology of the bone, leading in a large percentage of cases to a net increase in bone formation. Osteoprotegerin (OPG) plays a central role in controlling bone resorption. We have recently shown that CaP cells in bone exhibit increased levels of OPG and that serum levels of OPG are increased in patients with CaP bone metastases. The objective of this study was to investigate the effects of OPG over-expression on tumor-bone cell interactions. OPG-transfected C4-2 cells expressed 8001.5 pg OPG/ml/10 6  cells, while no OPG was detected in the media of C4-2 cells transfected with an empty plasmid. Conditioned media from OPG-C4-2 cells decreased osteoclast formation  in vitro . Subcutaneous OPG-C4-2 and control C4-2 tumors exhibited similar growth and take-rate characteristics and serum PSA levels. Expression of OPG  in vivo  was confirmed by immunohistochemistry and determination of serum OPG levels (74.8 pg OPG/ml/mm 3  of tumor). To evaluate tumor-bone cell interactions  in vivo  tumor cells were injected directly into tibiae of SCID mice. Animals were sacrificed at three or eight weeks after injection. Histomorphometric analysis of bone metastases at three weeks revealed no significant changes in bone characteristics or tumor volume between the groups. At eight weeks OPG-C4-2 cells caused increases in bone mineral density  vs.  C4-2 control cells (111.2 ± 1.7%  vs.  100.0 ± 3.3%, p=0.007). The percentage of bone volume in tissue volume was also increased in bone metastases of OPG-C4-2 cells  vs.  C4-2 cells (11.91 ± 1.57  vs.  5.08 ± 2.05, p=0.007). Osteoblast and osteoclast perimeters per bone perimeter were also decreased by overexpression of OPG (p=0.003 and 0.019, respectively). The percentage of tumor volume in tissue volume was significantly lower in OPG-C4-2  vs . C4-2 (32.85 ± 2.50  vs.  48.64 ± 1.11, p=0.0004). Our data indicate that overexpression of OPG in C4-2 cells present in the bone environment inhibits bone lysis associated with C4-2 bone metastasis, suggesting that OPG expressed in CaP patient bone metastases may be at least partially responsible for the development of osteoblastic bone lesions. Our results also suggest that in this model tumor growth may be suppressed by inhibition of bone lysis and the concomitant decrease in release of growth factors from bone extracellular matrix.
Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB)
Authors: Meera Shah, Marcello C. Laurenti, Chiara Dalla Man, Jing Ma, Claudio Cobelli, Robert A. Rizza, Adrian Vella
Journal: Metabolism (2018)
Abstract 16549: Eplerenone and Vascular Function in LOX-1 Overexpressing Mice on High-Fat Diet
Authors: Coy Brunssen, Johannes Rissler, Heike Langbein, Anja Hofmann, Andreas Deussen, Mirko Peitzsch, Peter Cimalla, Edmund Koch, Graeme Eisenhofer, Tatsuya Sawamura, Henning Morawietz
Journal: Circulation (2017)

Introduction: Experimental and clinical studies support a protective effect of blockade of the aldosterone-binding mineralocorticoid receptor (MR) in heart failure. The impact of MR antagonist eple...
53 Long term follow up of microscopic colitis
Authors: G Mohamed, P Crotty, D McNamara, N Breslin, BM Ryan
Journal: Gut (2017)

Background  Microscopic colitis (MC) has been increasingly diagnosed in recent years. The two main variants are lymphocytic colitis (LC) and collagenous colitis (CC).  Aim  To evaluate the long term natural history and follow-up of patients diagnosed with MC.  Method  Patients diagnosed with MC were identified from the histopathology department database in our institution. Clinical details were obtained through a combination of chart review and follow up telephone interview.  Results  Conclusions  MC is commonly associated with other autoimmune conditions. A significant proportion of patients had no follow-up/did not seek follow-up which raises the possibility that their symptoms were not problematic. Further follow-up of patients with MC is necessary to gain better insight into the natural history of this condition.
Bawa-Garba’s suspension is extended by six months owing to personal circumstances
Authors: Clare Dyer
Journal: BMJ (2018)

The Medical Practitioners Tribunal Service has suspended Hadiza Bawa-Garba for a further six months after she told the General Medical Council that personal circumstances meant she needed more time before facing a public review hearing.

The case of the trainee paediatrician sparked an outcry among doctors over the way the GMC exercised its powers, culminating in a decision by the government to strip it of its power of appeal.

Bawa-Garba was convicted of gross negligence manslaughter in November 2015 over the death of 6 year old Jack Adcock and suspended from the UK medical register for 12 months in June 2017.1 The GMC appealed the suspension decision to the High Court, which decided to …
Cord Blood Derived Natural Killer Cells Loaded with a Tetravalent Bispecific Antibody Construct (AFM13) As Off-the-Shelf Cell Therapy for CD30+ Malignancies
Authors: Lucila Kerbauy, Mecit Kaplan, Pinaki P Banerjee, Francesca Lorraine Wei Inng Lim, Ana Karen Nunes Cortes, May Daher, Mayela Carolina Mendt, Rafet Basar, Li Li, Muharrem Muftuoglu, Hila Shaim, Mayra Shanley, Enli Liu, Sonny Ang, Rong Cai, Vandana Nandivada, Richard E Champlin, Joachim Koch, Martin Treder, Elizabeth J. Shpall, Katy Rezvani
Journal: Blood (2018)